Collegium Pharmaceutical(US:COLL)2025-05-08 21:30Financial Performance - Q1 2025 net product revenues reached $177.8 million, a 23% increase year-over-year compared to $144.9 million in Q1 2024[17,41] - Adjusted EBITDA for Q1 2025 was $95.2 million, a 3% increase compared to $92.4 million in Q1 2024[41] - Adjusted operating expenses for Q1 2025 were $62.2 million, an 80% increase compared to $34.5 million in Q1 2024[41] - The company reaffirms its 2025 financial guidance, projecting net product revenues between $735 million and $750 million, representing an 18% year-over-year increase[43] - The company reaffirms its 2025 financial guidance, projecting adjusted EBITDA between $435 million and $450 million, representing a 10% year-over-year increase[43] - The company reaffirms its 2025 financial guidance, projecting adjusted operating expenses between $220 million and $230 million, representing a 49% year-over-year increase[43] Jornay PM Growth - Jornay PM near-term revenue expectations are projected to be greater than $135 million in 2025, representing a greater than 34% increase from $100.7 million in 2024[33] - Jornay PM prescriptions grew by 24% year-over-year in Q1 2025[17,29] - Market share in branded LA methylphenidate market increased by 22%[29] Capital Deployment and Debt - The company had $197.8 million in cash, cash equivalents, and marketable securities, up $35 million from December 2024[18] - Net debt to adjusted EBITDA at the end of Q1 2025 was approximately 1.5x[18] - A $25 million Accelerated Share Repurchase (ASR) program was authorized by the Board in May 2025[18,48]